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Abstract: Neglected tropical diseases caused by parasitic infections are an on-going 
and increasing concern and burden to human and animal health, having the most 
devastating effect on the world’s poorest countries. Building upon our previously 
reported triazole analogues, in this study we describe the synthesis and biological 
testing of other novel heterocyclic acetogenin-inspired derivatives, namely 
3,5-isoxazoles, furoxans and furazans. Several of these compounds maintain low 
micromolar levels of inhibition against Trypanosoma brucei, whilst having no 
observable inhibitory effect on mammalian cells, leading to the possibility of novel 
lead compounds for selective treatment. 
 
Neglected tropical diseases remain one of the largest concerns in the developing 
countries of Africa and the South Americas, both in terms of healthcare provision and 
financial impact on the economies of the World’s poorest countries. This ongoing 
threat has arisen from a lack of effective prevention methods and minimal financial 
incentive to develop new therapeutic agents.[1] One of these prevalent neglected 
tropical diseases which has attracted attention in recent years is African sleeping 
sickness or Human African Trypanosomiasis (HAT), caused by the protozoan parasite 
Trypanosoma brucei. HAT is a serious health concern in sub-Saharan Africa with >65 
million people at risk and with an annual mortality rate of approximately 9000 per 
annum[2] The World Health Organization (WHO) estimates 20,000 new cases of HAT 
per year based on reported cases, and has set an ambitious target to eradicate HAT by 
2020.[3] Current drug treatments are dependent upon the stage of HAT and are 
difficult to administer to patients, requiring lengthy infusion rates, and have varying 
degrees of human toxicity, while showing low efficacy towards the parasite.[4] The 
combination eflornithine/nifurtimox therapy (NECT) for stage 2 HAT has proven 
successful, but resistance to this combination therapy is emerging.[5] The lack of new 
effective therapeutic agents and the onset of drug resistance highlights the urgent need 
for the development of novel small molecule inhibitors of T. brucei as potential lead 
compound s in the quest for new and effective treatments for HAT.[6] 
 
Acetogenins are a class of polyketide secondary metabolites isolated from medicinal 
plants of the Annonaceae species, typically found in tropical regions of West Africa 
and South America.[7,8] Isolated in 2004 by Laurens et. al. from the roots of bush 
banana plant Uvaria chamae, chamuvarinin 1, displayed high levels of cytotoxicity 
towards the KB 3-1 cell line (IC50 = 0.8 nM).[9] In 2011, our group reported the first 
total synthesis of this unique tetrahydopyran-containing acetogenin and found 1 to 
exhibit unexpected trypanocidal activity in both the bloodstream and procyclic forms 
of T. brucei (Fig. 1).[10,11] Inspired by chamuvarinin, we sought to design a series of 
simplified acetogenin-like analogues retaining key structural and stereochemical 
features of the parent natural product. These simplified analogues were assembled 
from a pool of readily accessible chiral tetrahydropyran (THP) building blocks via 
Cu-mediated click chemistry.[12] These 1,4-triazole linked analogues, including 2, 
maintained high trypanocidal activity with modest selectivity profiles when compared 
against the human HeLa cell line. 
 
Fig. 1 Rationale of new T. brucei inhibitors inspired by acetogenins 
 
Following on from this success we sought to explore alternative heterocyclic linkers, 
in particular those that would directly attach the heterocycle spacer to the flanking 
THP rings, in close analogy to the acetogenins. This direct linkage serves to reduce 
the molecules’ available degrees of freedom and so potentially improve binding 
efficiency. Moreover we wished to expand the toolbox of available reactions 
employing our chiral THP building blocks as a source of molecular diversity. This 
paper describes the expansion of our methodology to new heterocycles: 
3,5-isoxazoles, furoxans and furazans, as well as their assessment as potential 
trypanocidal agents. 
 
Despite their prevalence in natural products and their presence in several important 
drug compounds (e.g. valdecoxib, leflunomide, cloxacillin),[13] synthetic routes to 
aliphatic isoxazoles remain extremely limited.[14] In particular, there are only limited 
examples of α-oxygenated 3,5-isoxazoles and none of these, to our knowledge, have 
been prepared in enantioenriched form. Our approach employs the coupling of chiral 
α-oxygenated alkynes with in situ prepared nitrile oxides, derived from the 
corresponding oximes, in a [3+2] cycloaddition. Oximes 3-5 were rapidly accessed 
from the corresponding THP alcohols by Swern oxidation and condensation with 
hydroxylamine (Scheme 1). Synthesis of the required alkyne-substituted THP 
precursors 6-8 have been previously described.[10,12]  
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Scheme 1 Synthesis of oximes 3-5: a) (COCl)2, DMSO, CH2Cl2, Et3N, -78 °C → RT; 
b) NH2OH•HCl, EtOH, 0 °C → RT. 
 
A screen of isoxazole-forming reaction conditions, focused on the choice of oxidising 
agent (required to generate the nitrile oxide) found that t-butylhypochlorite was 
essential as the oxidising agent.[15,16] These conditions were successfully applied 
across a range of substrates with varying side-chain substitution and THP 
stereochemistry giving isoxazoles 9-13 (Scheme 2). Yields were generally modest, 
but nonetheless rapidly generated sufficient quantities of these synthetically 
demanding substrates for biological evaluation.  
 
 
Scheme 2 Synthesis of isoxazoles 9-13: a) t-BuOCl then Et3N, -78 °C → RT. 
 
Screening results for our compounds against procyclic and bloodstream forms of T. 
brucei are outlined in Table 1. Also included are the results of HeLa cell line 
screening which we have employed as a representative human cell line to assess our 
analogues’ selectivity. In general, the isoxazole motif was well tolerated with 
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comparable activity towards T. brucei being maintained to the original triazole 
analogues. The THP stereochemistry had a significant influence on potency with the 
syn-syn compounds 9 and 10 and anti-anti 13 most potent. This is in contrast to our 
original triazole series where anti-anti analogues were generally inactive.[12] Of 
particular interest were the good levels of selectivity displayed across the series 
against T. brucei over mammalian HeLa cells, with all but one of the analogues 
greater than 100 µM against HeLa cells. 
 
Table 1 Biological data for isoxazoles 9-13: (a) Selectivity Index refers to HeLa EC50 
/ T. brucei EC50 
 
 
 
Entry 
 
Analogue 
T. brucei  
(BSF)  EC50  
(µM) 
T. brucei  
(insect) EC50 
(µM) 
HeLa 
EC50 
(µM) 
Selectivity 
Indexa 
1 9 4.5 ± 0.2 19.6 ± 3.1 107.8 ± 4.9 24 
2 10 9.0 ± 0.6 43.8 ± 4.0 >200 >22 
3 11 30.9 ± 1.4 69.3 ± 5.1 >200 >6.5 
4 12 17.4 ± 0.5 >60 68.8 ± 6.8 4.0 
5 13 5.6 ± 0.2 16.6 ± 2.2 >100 >18 
 
 
In the preparation of the isoxazole analogues, we identified significant by-product 
formation- namely the furoxan arising from nitrile oxide dimerization.[17] These could 
be isolated in trace amounts but were more productively generated by simply 
warming the reaction after nitrile oxide formation in order to induce dimerization (in 
the absence of alkyne). This generated furoxans 14-16 in useful quantities (Scheme 
3). While interesting in their own right, these compounds also allowed rapid access to 
furazans 17-19 by simple reduction with triethyl phosphite. 
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 Entry Oxime Furoxan Yield (%) Furazan Yield (%) 
1 3 14 44 17 67 
2 4 15 61 18 77 
3 5 16 64 19 59 
Scheme 3 Synthesis of furoxans 14-16 and furazans 17-19: a) t-BuOCl then Et3N, -
78 °C → RT; b) P(OEt)3, reflux. 
 
Screening of these compounds revealed that furoxans also displayed encouraging T. 
brucei activity with anti-anti analogue 15 most potent and 5.6 times more selective 
over HeLa cells (Table 2, entry 2).[18] Pleasingly, select furazan compounds maintain 
good T. brucei inhibition, while being essentially inactive towards HeLa (18, >44-fold 
selectivity, entry 5). The selectivity observed in this instance merits further detailed 
study of this unusual heterocyclic framework.  
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Table 2 Biological data for furoxans 14-16 and furazans 17-19: (a) Selectivity Index 
refers to HeLa EC50 / T. brucei EC50 
 
 
Entry 
 
Analogue 
T. brucei  
(BSF)  EC50  
(µM) 
T. brucei  
(insect) EC50 
(µM) 
HeLa 
EC50 
(µM) 
Selectivity 
Indexa 
1 14 8.7 ± 0.4 >50 66.6 ± 6.8 7.7 
2 15 4.5 ± 0.3 5.5 ± 0.2 25.4 ± 12.6 5.6 
3 16 63.8 ± 5.3 >500 >500 >7.8 
4 17 16.3 ± 0.5 26.6 ± 1.9 142.9 ± 17.3 8.8 
5 18 11.3 ± 0.6 >100 >500 >44 
6 19 146 ± 7.7 >500 >500 >3.4 
 
 
We have demonstrated the utility of our chiral THP building blocks by their 
elaboration to oximes and their use in ‘Click’ reactions with alkynes to generate 
complex isoxazole products. Moreover, dimerization of these oximes allows access to 
furoxan and furazan heterocycles. All series tested show encouraging low micromolar 
activity in T. brucei and excellent selectivity over mammalian cells in certain cases. 
These selectivities are a significant improvement over our previously described 
triazole compounds and can serve as a basis for further optimization. Current efforts 
are focused on other heterocyclic spacers as well as the synthesis of fluorescent and 
affinity tagged versions in order to isolate target protein(s) allowing us to establish the 
trypanocidal mode of action. 
 
Keywords Trypanosomatid, drug discovery, natural product analogues, [3+2] 
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Text for the Table of Contents 
Taking inspiration from Nature, a series of bis-tetrahydropyran substituted N,O-
heterocyclic inhibitors, based on the acetogenin chamuvarinin, were prepared and 
assessed for trypanocidal activity in T. brucei. Several of these simplified analogues 
display selective trypanocidal effects with no observable toxicity towards mammalian 
cell lines. 
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